Development and evaluation of rapid data-enabled access to routine clinical information to enhance early recruitment to the national clinical platform trial of COVID-19 community treatments

Competing Interest Statement

Competing interests CCB and FDRH are the co-PIs for PRINCIPLE, CC, DS, SM and AM are employees of Health Data Research UK.

Clinical Trial

ISRCTN86534580

Funding Statement

Funding PRINCIPLE is funded by UKRI Urgent Public Health Priority COVID scheme. FDRH acknowledges part-funding from the National Institute for Health Research (NIHR) School for Primary Care Research, the NIHR Collaboration for Leadership in Health Research and Care (CLARHC) Oxford, the NIHR Oxford Biomedical Research Centre (BRC, UHT), and the NIHR Oxford Medtech and In-Vitro Diagnostics Co-operative (MIC). The National Core Study Data & Connectivity programme is funded by UKRI. Health Data Research UK receives core funding from Medical Research Council (MRC), Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social Care, Health and Care Research Wales, Chief Scientists Office (Scotland), Public Health Agency (Northern Ireland), Wellcome and British Heart Foundation; together known as the Core Funders. NHS DigiTrials receives funding from the Digital Innovation Hubs programme, led by HDR UK. NHS Digital receives funding from the Data & Connectivity National Core Study, this has been used to fund the service delivery described in this paper. MJL receives core funding from HDR UK, NIHR Oxford Biomedical Research Centre, and MRC Population Health Research Unit. PFC is a Wellcome Trust Principal Research Fellow (212219/Z/18/Z), and a UK NIHR Senior Investigator, who receives support from the Medical Research Council Mitochondrial Biology Unit (MC_UU_00015/9), the Medical Research Council (MRC) International Centre for Genomic Medicine in Neuromuscular Disease (MR/S005021/1), the Leverhulme Trust (RPG-2018-408), an MRC research grant (MR/S035699/1), an Alzheimer's Society Project Grant (AS-PG-18b-022) and the National Institute for Health Research (NIHR) Biomedical Research Centre based at Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This trial has been ethically reviewed and approved by the South Central Berkshire Research Ethics Committee on the 26th March 2020 (REC reference: 20/SC/0158).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes